Searchable abstracts of presentations at key conferences in endocrinology

ea0081p288 | Calcium and Bone | ECE2022

Tumour induced osteomalacia: 2 years treatment with burosumab

Aliberti Ludovica , Pontrelli Margherita , Verrienti Martina , Gagliardi Irene , Zatelli Maria Chiara , Ambrosio Maria Rosaria

Introduction: Tumor-induced osteomalacia (TIO) is a paraneoplastic syndrome due to an overproduction of fibroblast growth factor 23 (FGF23) by small and benign mesenchimal tumors. FGF23 increase causes hypophosphatemia, osteomalacia and muscle weakness. TIO is usually cured by tumour resection, but neoplasms may be unidentifiable/unresectable or the patient may refuse surgery. In these cases, medical treatment with high doses of oral phosphate and calcitriol is mandatory, even...

ea0073pep5.2 | Presented ePosters 5: Thyroid | ECE2021

Low-risk papillary thyroid carcinoma: outcome predictive factors in a cohort of patients not treated with radioiodine therapy after total thyroidectomy

Gagliardi Irene , Mella Alessandro , Rossi Roberta , Pontrelli Margherita , Rossi Martina , Chiara Zatelli Maria

BackgroundPapillary thyroid carcinoma (PTC) is the most frequent thyroid malignant neoplasm. American Thyroid Association (ATA) guidelines don’t specify how to follow-up low-risk PTC patients not receiving radioiodine therapy (RAI) after total thyroidectomy (TT). Indeed, there is no consensus among authors regarding the interpretation of thyroglobulin (TG) levels and ultrasound neck (US) findings during follow-up in these settings.<p class="abst...